Article
Oncology
Aaron N. Holmes, Helen Swede, Wendy M. Feer, Donna Comins Pike, Xiaoyan Wang, Upendra P. Hegde
Summary: Patients with non-cutaneous cancer have a higher prevalence of autoimmunity compared to those with melanoma only or no cancer history. Among patients with metastases at initial presentation, those with a history of melanoma and non-cutaneous cancer show a higher prevalence of autoimmunity. Patients over 75 years old have the highest odds of autoimmunity compared to other age groups.
Article
Oncology
James L. Alexander, Hajir Ibraheim, Bhavisha Sheth, Jessica Little, Muhammad Saheb Khan, Camellia Richards, Nikki Hunter, Dharmisha Chauhan, Raguprakash Ratnakumaran, Kathleen McHugh, David J. Pinato, Paul Nathan, Julia Choy, Shanthini M. Crusz, Andrew Furness, Samra Turajlic, Lisa Pickering, James Larkin, Julian P. Teare, Sophie Papa, Ally Speight, Anand Sharma, Nick Powell
Summary: This study investigated the outcomes of patients with corticosteroid-refractory CPI-induced enterocolitis treated with IFX, finding that less than half of patients achieved corticosteroid-free clinical remission. The data also suggest that cancer outcomes may be better in patients developing prolonged and severe inflammatory side effects of CPI therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Lauren J. Brown, Alison Weppler, Prachi Bhave, Clara Allayous, J. Randall Patrinely, Patrick Ott, Shahneen Sandhu, Andrew Haydon, Celeste Lebbe, Douglas B. Johnson, Georgina V. Long, Alexander A. Menzies, Matteo S. Carlino
Summary: This study retrospectively analyzed 55 patients with advanced melanoma who received combination therapy of ipilimumab and anti-PD1, showing that in patients with pre-existing autoimmune diseases not on immunosuppression, the safety and efficacy of combination therapy were similar to previously reported trials. However, there may be a risk of flare of pre-existing autoimmune diseases in certain patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Pankti Reid, David F. L. Liew, Rajshi Akruwala, Anne R. Bass, Karmela K. Chan
Summary: The study identified a new adverse event of ICI immunotherapy called post-ICI-activated osteoarthritis (ICI-aOA). Patients with ICI-aOA experienced increased joint pain after ICI treatment, affecting joints commonly seen in osteoarthritis such as large joints (hip/knee) and small joints in the hands.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Mario Sznol
Summary: Treatment with anti-PD-1 and/or BRAF-targeted therapies prior to metastatic melanoma was associated with limited activity of tumor infiltrating lymphocytes (TIL). Recent insights into the mechanisms of action for TIL and anti-PD-1 provide a foundation for understanding differences in outcomes in various trials or populations, and offer a roadmap for developing improved products.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Robert H. I. Andtbacka, Brendan Curti, Gregory A. Daniels, Sigrun Hallmeyer, Eric D. Whitman, Jose Lutzky, Lynn E. Spitler, Karl Zhou, Praveen K. Bommareddy, Mark Grose, Meihua Wang, Cai Wu, Howard L. Kaufman
Summary: The study evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable melanoma. Results showed that V937 was well tolerated and showed promising efficacy, warranting further investigation. Studies on combination approaches with V937 and immune checkpoint inhibitors are ongoing.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
M. Bryana Cassie, Gabriel J. Rocklin, Matthew J. Bick, Alex Ford, Sonia Majri-Morrison, Ashley V. Kroll, Chad J. Miller, Lauren Carter, Inna Goreshnik, Alex Kang, Frank DiMaio, Kristin V. Tarbell, David Baker
Summary: The PD-1 pathway plays a crucial role in regulating immune responses, and the computationally designed hyperstable PD-1 binding protein PD-MP1 acts as an agonist that strongly inhibits murine T cell activation, offering a new approach for the treatment of autoimmune and inflammatory diseases.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Immunology
Ningyue Sun, Yangzi Tian, Yuhan Chen, Weinan Guo, Chunying Li
Summary: Melanoma is a lethal type of skin cancer that is characterized by disordered metabolism. Metabolic rewiring in melanoma not only affects tumor cell behaviors but also interferes with antitumor immunity by influencing the functions of surrounding immune cells. This review summarizes the epidemiology, clinical characteristics, and treatment proceedings of melanoma, as well as the roles of immune cells and metabolic rewiring in tumor immunology.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Glenn F. van Wigcheren, Daphne Roelofs, Carl G. Figdor, Georgina Florez-Grau
Summary: Current treatments for autoimmune diseases involve long-term drug regimens that broadly dampen immune responses, leading to severe side effects and creating a need for safer and more effective therapy. Cell-based immunotherapy using tolerogenic CD14+ myeloid cells offers a promising alternative, with different cell types having distinct cellular properties and immunosuppressive mechanisms. However, each cell type faces unique challenges in development towards immunotherapy, highlighting the potential benefits and risks of novel cell-based therapies for autoimmune diseases.
JOURNAL OF AUTOIMMUNITY
(2021)
Article
Pharmacology & Pharmacy
Fatemeh Zahedipour, Parvin Zamani, Khadijeh Jamialahmadi, Mahmoud Reza Jaafari, Amirhossein Sahebkar
Summary: Angiogenesis plays a significant role in the metastasis and progression of melanoma. Vaccines targeting angiogenesis in melanoma, including specific immunotherapy, show promise in inducing strong anti-tumor immune responses by targeting genetically stable endothelial cells. Various types of vaccines, such as DNA, peptide, protein, dendritic cell-based, and endothelial cell vaccines, have been studied to target angiogenesis in melanoma for potential progress in developing effective treatments.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Review
Immunology
Qi Jiang, Xin Wang, Enyu Huang, Qiao Wang, Chengping Wen, Guocan Yang, Liwei Lu, Dawei Cui
Summary: Inflammasome is a cellular complex involved in the innate inflammatory response, and its excessive or abnormal activation has been implicated in various diseases. In rheumatoid arthritis, inflammasome activation plays a key role in immune dysregulation and joint inflammation. This review summarizes recent research on inflammasome activation and its effector mechanisms in the pathogenesis of rheumatoid arthritis, as well as potential therapeutic strategies.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Noemie Joalland, Kathleen Ducoin, Gwenann Cadiou, Catherine Rabu, Carole Guillonneau
Summary: The 24th annual NAT conference and the 4th biennial LabEx IGO meeting were held jointly around the theme of new horizons in immunotherapy, highlighting new findings in the fields of transplantation, autoimmunity, and cancer on May 31st and June 1st, 2021.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Ranjeny Thomas, Jose M. Carballido, Johnna D. Wesley, Simi T. Ahmed
Summary: Antigen-specific immunotherapy shows promise for treating type 1 diabetes, but faces obstacles in clinical translation. The key to overcoming these challenges lies in collaboration and cooperation among various stakeholders.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Naomi Benne, Danielle ter Braake, Arie Jan Stoppelenburg, Femke Broere
Summary: This article discusses the strategy of using nanoparticles to deliver antigens and restore immune tolerance. It highlights potential cell targets and application methods for nanoparticles, as well as how nanoparticles carrying immunomodulators can activate tolerance in other antigen-presenting cell types. It also emphasizes the importance of considering relevant factors when translating animal studies to clinical applications.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Funda Meric-Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Mueller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc Pelletier, Shahneen Sandhu
Summary: This study assessed the safety and tolerability of the combination of MIW815 and spartalizumab in patients with advanced solid tumors or lymphomas. The results showed that the combination therapy had immune activation but limited antitumor activity.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Shahneen Sandhu, Victoria Atkinson, Maria Gonzalez Cao, Theresa Medina, Ainara Soria Rivas, Alexander M. Menzies, Ivor Caro, Louise Roberts, Yuyao Song, Yibing Yan, Yu Guo, Cloris Xue, Georgina V. Long
Summary: The efficacy and safety of cobimetinib plus atezolizumab in the treatment of advanced BRAFV600 wild-type melanoma patients who failed prior anti-PD-1 therapy were evaluated. The results showed limited activity of this combination therapy in patients with disease progression on or after prior anti-PD-1 therapy.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, James Larkin, Victoria Atkinson, Michael Schenker, Jacopo Pigozzo, Helen Gogas, Stephane Dalle, Nicolas Meyer, Paolo A. Ascierto, Shahneen Sandhu, Thomas Eigentler, Ralf Gutzmer, Jessica C. Hassel, Caroline Robert, Matteo S. Carlino, Anna Maria Di Giacomo, Marcus O. Butler, Eva Munoz-Couselo, Michael P. Brown, Piotr Rutkowski, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis de la Cruz-Merino, Andrew Haydon, Jean-Jacques Grob, Jacob Schachter, Paola Queirolo, Luis De La Cruz-Merino, Andre van der Westhuizen, Alexander M. Menzies, Sandra Re, Tuba Bas, Veerle de Pril, Julia Braverman, Daniel J. Tenney, Hao Tang, Georgina Long
Summary: The CheckMate 915 trial compared adjuvant nivolumab plus ipilimumab with nivolumab alone in patients with resected melanoma. The study found that there was no significant difference in recurrence-free survival between the two treatment groups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jason A. Chesney, Antoni Ribas, Georgina Long, John M. Kirkwood, Reinhard Dummer, Igor Puzanov, Christoph Hoeller, Thomas F. Gajewski, Ralf Gutzmer, Piotr Rutkowski, Lev Demidov, Petr Arenberger, Sang Joon Shin, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Johannes van Thienen, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J. Diede, James R. Anderson, Sheryl Treichel, Edward L. Chan, Sumita Bhatta, Jennifer Gansert, Frank Stephen Hodi, Helen Gogas
Summary: In this phase III study, the combination of T-VEC and pembrolizumab did not significantly improve progression-free survival or overall survival in patients with advanced melanoma. These findings indicate that this combination therapy is not effective in this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Oncology
Sunandana Chandra, Jacob S. S. Choi, Jeffrey A. A. Sosman
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
J. M. Versluis, A. M. Menzies, K. Sikorska, E. A. Rozeman, R. P. M. Saw, W. J. van Houdt, H. Eriksson, W. M. C. Klop, S. Ch'ng, J. V. van Thienen, H. Mallo, M. Gonzalez, A. Torres Acosta, L. G. Grijpink-Ongering, A. van der Wal, A. Bruining, B. A. van de Wiel, R. A. Scolyer, J. B. A. G. Haanen, T. N. Schumacher, A. C. J. van Akkooi, G. V. Long, C. U. Blank
Summary: Neoadjuvant ipilimumab plus nivolumab has shown high short-term survival rates in patients with macroscopic stage III melanoma, especially for those with a pathologic response. Pathologic response is the strongest predictor for long-term outcome.
ANNALS OF ONCOLOGY
(2023)
Letter
Oncology
Sunandana Chandra, Jacob S. Choi, Jeffrey A. Sosman
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Editorial Material
Biochemistry & Molecular Biology
Claus Garbe, Reinhard Dummer, Teresa Amaral, Rodabe N. Amaria, Paolo A. Ascierto, Elizabeth M. Burton, Brigitte Dreno, Alexander M. M. Eggermont, Axel Hauschild, Christoph Hoeller, Roland Kaufmann, Celeste Lebbe, Mario Mandala, Alexander M. Menzies, David Moreno, Olivier Michielin, Paul Nathan, Sapna P. Patel, Caroline Robert, Dirk Schadendorf, Paul C. Lorigan, Richard A. Scolyer, Hussein A. Tawbi, Bart A. van de Wiel, Christian Blank, Georgina V. Long
Summary: Individuals with cutaneous melanoma who receive neoadjuvant immunotherapy demonstrate significant improvement, which should be included in standard care.
Article
Oncology
Ryan C. Augustin, Ziyu Huang, Fei Ding, Shuyan Zhai, Jennifer McArdle, Anthony Santisi, Michael Davis, Cindy Sander, Diwakar Davar, John M. Kirkwood, Greg M. Delgoffe, Allison Betof Warner, Yana G. Najjar
Summary: In this study, it was found that metformin treatment in diabetic melanoma patients is associated with lower recurrence rates, higher survival rates, and reduced incidence of brain metastases.
FRONTIERS IN ONCOLOGY
(2023)
Article
Medicine, General & Internal
Georgina Long, Susan M. Swetter, Alexander M. Menzies, Jeffrey E. Gershenwald, Richard A. Scolyer
Summary: Cutaneous melanoma is a malignancy derived from skin melanocytes, primarily caused by ultraviolet radiation. Diagnosis is based on clinical and histopathological findings, and treatment options vary depending on disease stage and characteristics. Multidisciplinary care, including systemic drug therapies, has significantly improved melanoma survival rates.
Article
Oncology
Caroline A. Gjorup, Ines Pires da Silva, Linda Martin, Jonathan R. Stretch, Richard A. Scolyer, Georgina Long, Angela Hong
Summary: Two cases of primary desmoplastic melanoma of the nose were successfully treated with anti-PD-1 checkpoint inhibitor and radiation therapy, which provided good outcomes and cosmetic results. This suggests that PD-1 blockade and radiation therapy can be a safe alternative option for desmoplastic melanoma where surgery is morbidly disfiguring.
Meeting Abstract
Oncology
Allison Betof Warner, Michael A. Postow, Katherine Panageas, James William Smithy, Adam Jacob Schoenfeld, Jedd D. Wolchok, Alexander Noor Shoushtari
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Clinical Neurology
Rachna Malani, Ankush Bhatia, Allison Betof Warner, Jonathan T. Yang
Summary: Leptomeningeal metastases/diseases (LMDs) are a late-stage complication of solid tumor or hematologic malignancies. It is a disseminated disease which significantly affects the neurological system. Our understanding of its pathophysiology is currently lacking, but treatment strategies are constantly improving.
SEMINARS IN NEUROLOGY
(2023)